association

Full identifier: http://purl.org/np/RAcsh1NcsYk7ZHJsJfR5-rVirsHKebUu_f8IMTLmosgjw#association

Assigned to 1 class:

Minted in Nanopublication

 RAcsh1NcsY comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RAcsh1NcsY... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T11:31:45.585+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAcsh1NcsY... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAcsh1NcsY... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAcsh1NcsY... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:31:45.585Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings sulindac tablets usp are indicated for acute or long term use in the relief of signs and symptoms of the following osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitis supraspinatus tendinitis acute gouty arthritis the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no self care
Leoni Bücken
2021-07-03T09:31:45.585Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:31:45.585Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:31:45.585Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:31:45.585Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:31:45.585Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:31:45.585Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:31:45.585Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)